Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor ...

Carisma Therapeutics Inc.  ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming ...

Corticosteroids inhibit antigen presentation, cytokine production ... The monocyte effect. Monocytes/macrophages (promonocytes in the bone marrow, circulating monocytes, tissue macrophages ...

Acute-on-chronic liver failure (ACLF) is a life-threatening condition characterized by acute deterioration of liver function ...

Ulcerative colitis (UC) is a chronic gut inflammatory condition affecting the colon in humans. This study uses human samples as well as a mouse model of colitis induced by a chemical, DSS, to ...

Liver failure encompasses a range of severe clinical syndromes resulting from the deterioration of liver function, triggered ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...

receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.TEVIMBRA is the foundational ...

COYA 301 is the company’s proprietary investigational low-dose interleukin-2 (IL-2) intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and is designed for subcutaneous ...